HowShorted

How shorted is Moleculin Biotech, Inc.?

More shorted than 99% of the 2,877 ranked US companies

29.56%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
+9.80
5 reports (~10 weeks)
+19.67
Aggregate net short position time series for Moleculin Biotech, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202629.56%+9.80
15 Jul 202619.76%−6.73
30 Jun 202626.49%+4.85
15 Jun 202621.64%+6.11
29 May 202615.53%+5.64
15 May 20269.89%+3.62
30 Apr 20266.27%+3.67
15 Apr 20262.60%+0.47
31 Mar 20262.13%+0.08
13 Mar 20262.05%−5.38
28 Nov 20257.43%−2.96
14 Nov 202510.39%−18.38
31 Oct 202528.77%+15.83
15 Oct 202512.94%+3.62
30 Sep 20259.32%+1.57
15 Sep 20257.75%−1.38
29 Aug 20259.13%−1.76
15 Aug 202510.89%−18.13
31 Jul 202529.02%–

Frequently asked questions

How shorted is Moleculin Biotech, Inc. right now?
29.56% of Moleculin Biotech, Inc.'s (MBRX) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.